Gamma-hydroxybutyrate Salts for Learning Disorder Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for dyslexia and other learning disorders are primarily behavioral and lack medical interventions, with no approved medications to effectively address the underlying difficulties in reading, writing, and cognitive processing.

Innovation Solution

The use of gamma-hydroxybutyrate salts, specifically calcium oxybate, magnesium oxybate, and sodium oxybate, administered orally in specific weight-to-weight ratios, to treat dyslexia and other learning disorders such as dysnomia, dyspraxia, dyscalculia, ADHD, and autism spectrum disorder.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If behavioral treatment interventions are used for dyslexia, then treatment can be implemented without medications, but there is no approved medical intervention to effectively address the underlying difficulties

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidcomplexity of treatment approach

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by transitioning from behavioral interventions to pharmacological treatment using gamma-hydroxybutyrate salts. This involves changing the fundamental parameter of treatment modality from non-pharmacological to pharmacological, thereby introducing a new parameter (medical intervention) that directly addresses the underlying neurological difficulties of dyslexia and related learning disorders.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If no medications are approved for treating dyslexia, then safety concerns are avoided, but effective medical treatment is unavailable

Engineering Contradiction:

Improveavailability of effective treatmentVSAvoidlack of approved medical intervention

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses gamma-hydroxybutyrate salts as an intermediary substance to bridge the gap between available treatments and effective medical intervention. This intermediary compound acts as a mediator that can cross the blood-brain barrier and modulate neurotransmitter systems, providing a mechanism for effective treatment while maintaining safety through established pharmacological pathways.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If behavioral interventions are implemented, then accommodations can be made for reading and writing, but the underlying cognitive processing difficulties remain unaddressed

Engineering Contradiction:

Improveimplementation of accommodationsVSAvoidaddressing underlying difficulties

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent applies preliminary action by using gamma-hydroxybutyrate salts to pre-treat and optimize cognitive processing functions before educational interventions are implemented. This preliminary pharmacological optimization prepares the neurological substrate to better respond to reading, writing, and cognitive tasks, thereby enhancing the effectiveness of subsequent behavioral accommodations and interventions.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS11877992B1Gamma-hydroxybutyrate salts for the treatment of learning disorders

Publication Date: 2024.01.23 SPINELLI KELLY KATHLEEN

AI summary

A method of treating dyslexia and/or other learning disorders comprises administering at least one gamma-hydroxybutyrate salt.